In regulatory news:

FDA officials and representatives from both the generic and branded drug industries spent two days hashing out next steps for development of abuse-deterrent opioids. According to MedPage Today, the two topics on the table were reviewing draft guidance for the development of generic versions of abuse-deterrent opioids and developing a standard in vitro testing methods to characterize a drug’s abuse-deterrent properties. The meeting is in line with the FDA’s strategic plan for mitigating the opioid epidemic.

Read complete coverage here.

Leave a Comment

Your email address will not be published. Required fields are marked *